종목/WST
West Pharmaceutical Services, Inc.
Second quarter 2026: Net sales $830 million to $850 million (reported growth 8.3% to 10.9%; organic growth 7.0% to 9.6%); Adjusted-diluted EPS $2.05 to $2.12.
Full-year 2026: Net sales $3.295 billion to $3.350 billion (reported growth 7.2% to 9.0%; organic growth 7% to 9%); Adjusted-diluted EPS $8.40 to $8.75. Capital spending guidance $250 million to $275 million. (회사 제시 내용 그대로)
아래 내용은 AI 가 8-K Item 2.02 본문과 보도자료(Exhibit 99.x)를 종합해 한국어로 정리한 요약입니다. 핵심 하이라이트·가이던스·운영 코멘트·시장 평가 네 섹션 모두 AI 생성이며, 실제 원문은 EDGAR 링크에서 확인하세요.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 4월 23일 (목) | 2026 Q1 | $1.69 | $2.13 | +25.8% | $845M | — |
| UNH | 유나이티드헬스 | 345B | +8.9% | 75% (3/4) |
| MRK | 머크 | 275B | +16.0% | 100% (4/4) |
시장 관점에서는 실적의 견조한 유기적 성장, 조정 EPS 증가 및 가이던스 상향으로 긍정적(beat) 반응이 예상된다. 다만 1회성 세금비용 및 SmartDose 매각에 따른 포트폴리오·유기성 비교 영향, 대규모 자사주 매입으로 현금 감소 등은 투자자가 주의할 리스크 요인이다.